ProtoKinetix, Incorporated filings document the regulatory record for a Nevada clinical-stage biomedical company developing AAGP®/PKX-001 applications. Recent Form 8-K and 8-K/A reports cover Regulation FD stockholder updates, leadership and board changes, and amendments to previously furnished company communications.
Proxy and consent-solicitation materials describe stockholder approval of an amendment to the articles of incorporation increasing authorized common shares. The filing record also includes Form 12b-25 notices related to annual-report timing and disclosures on the company’s common-stock authorization, governance actions, and public-company reporting status.
ProtoKinetix, Inc. (PKTX) reported a net loss of $77,726 for the three months ended March 31, 2026, compared with $97,690 a year earlier. The development-stage medical research company says it has not developed a commercially viable product or generated significant revenue. Research and development expense was $24,220, versus $33,810, and net cash used in operating activities was $23,616, versus $51,970.
Cash was $524 and working capital was negative $235,879 at March 31, 2026. Management said additional equity and/or debt financing is required to meet cash-flow projections and continue business objectives; the company disclosed substantial doubt about its ability to continue as a going concern. Disclosure controls were ineffective as of November 4, 2026. After quarter-end, it issued convertible notes for the purchase of 16,540,000 common shares, with gross proceeds of $165,400. On April 30, 2026, it issued 2,100,000 shares in a private placement for gross proceeds of $21,000. ProtoKinetix formed SightPath Biotech LLC on February 11, 2026, to develop PKX-001 for dry-eye and other ocular diseases; the subsidiary had no operating activity.
ProtoKinetix, Inc. amended its notice for an equity offering, identifying Rule 506(b) and Securities Act Section 4(a)(5) as exemptions claimed. It reports $205,500 USD sold and $44,500 USD remaining to be sold. The notice dates the first sale to September 25, 2025, and lists $0 USD in finders’ fees.
ProtoKinetix, Inc. (PKTX) filed its annual report as a development-stage biotechnology company focused on anti-freeze glycoproteins (AAGP®) for cell, tissue and organ preservation and other medical uses. The company remains pre-revenue and is concentrating on research collaborations and commercial validation of its AAGP® technology.
For the year ended December 31, 2025, ProtoKinetix reported a net loss of $393,650, slightly higher than the $364,188 loss in 2024, driven mainly by $177,610 in professional fees and $106,613 in research and development expenses. Cash at year-end was only $1,118, with a working capital deficiency of $183,266 and an accumulated deficit of $48.6 million, and the auditor and management both state that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
During 2025, the company raised $197,500 through common stock sales, issued shares for consulting services and to settle debt, and capitalized $56,308 of patent-related intangible assets, bringing intangible assets to $481,206. Management discloses material weaknesses in internal control over financial reporting, including insufficient segregation of duties and limited formal corporate governance documentation. As of December 31, 2025, 406,830,152 common shares were outstanding, increasing to 411,630,152 shares by September 3, 2026.
Protokinetix, Inc. notified investors that it will file its Quarterly Report on Form 10‑Q for the period ended June 30, 2026 after the deadline. The company cites delays in completing its financial statements and management’s discussion and analysis, and additional time needed by its independent registered public accounting firm to complete its review.
Under Rule 12b‑25, Protokinetix expects to file the report no later than the fifth calendar day following the original due date of August 14, 2026, which applies to smaller reporting companies.
ProtoKinetix, Inc. director Jason G. Lamp reports ownership of 6,496,878 shares of the company’s Common Stock. The position is reported as directly held as of 2026-06-17, with no accompanying purchase or sale transactions disclosed.
ProtoKinetix, Inc. director and President Keith R. Brunt filed an initial ownership report showing his equity position in the company. He reports indirect ownership of 1,030,000 shares of Common Stock held by NBBM Inc. and direct ownership of 2,042,572 shares of Common Stock.
Brunt also reports stock options over 2,750,000 shares of Common Stock with an exercise price of $0.01 per share, expiring on December 6, 2030, issued under the company’s 2019 Equity Incentive Plan. This filing records existing holdings rather than reporting new buy or sell transactions.
ProtoKinetix, Inc. director Michael Winston Jones filed an initial ownership report on Form 3. The filing shows he directly holds 6,400,000 shares of Common Stock after the reported date. This is a disclosure of existing holdings, not a report of a new stock purchase or sale.
ProtoKinetix, Inc. reported several corporate updates. Longtime director Edward McDonough resigned from the board, stating his decision was not due to any disagreement with the company. The board then appointed Michael Jones and Jason Lamp as new directors, and named translational scientist Dr. Keith Brunt as both a director and president.
The company formed a wholly owned subsidiary, SightPath Biotech LLC, to develop its PKX-001 synthetic glycopeptide for dry-eye disease and other ocular conditions. Two independent analyses in 2021 and 2025 estimated the present value of related patents and development work at approximately $253 million, reflecting factors such as novel IP, market size, and competitive position.
ProtoKinetix disclosed that it filed Form 12b-25 notices for delayed filing of its 2025 annual report and first-quarter 2026 quarterly report and is working on completing these filings. The board also approved repricing options covering 61,190,000 shares and warrants for 6,000,000 shares from a $0.028 to $0.01 exercise price and extended their expiration dates by two years.
Protokinetix, Inc. submitted a Form 12b-25 notifying the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because of delays completing financial statements and management's discussion and analysis.
The company states the independent registered public accounting firm requires additional review time and that it anticipates filing the Quarterly Report no later than the fifteenth calendar day following the prescribed due date. The notification is signed by CEO Michael Guzzetta dated May 15, 2026.
Protokinetix, Inc. submitted a Form 12b-25 notifying the SEC it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 due to delays finalizing financial statements and MD&A. The registrant states it expects to file the Annual Report no later than the fifteenth calendar day following the prescribed due date for smaller reporting companies (original filing date March 31, 2026). The notification was executed by Michael Guzzetta on March 31, 2026.